Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) has been given a consensus recommendation of "Moderate Buy" by the eight brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $8.69.
A number of equities analysts have commented on DNA shares. Bank of America lowered Ginkgo Bioworks from a "neutral" rating to an "underperform" rating and set a $3.00 price objective on the stock. in a research note on Wednesday, May 18th. BTIG Research raised their price objective on Ginkgo Bioworks from $5.00 to $6.00 and gave the stock a "buy" rating in a research note on Tuesday, August 16th. Raymond James raised their price objective on Ginkgo Bioworks from $11.50 to $14.50 and gave the stock an "outperform" rating in a research note on Tuesday, August 16th. Finally, Jefferies Financial Group lowered their price objective on Ginkgo Bioworks from $11.50 to $4.35 in a research note on Thursday, June 16th.
Get Ginkgo Bioworks alerts:Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Lincoln National Corp bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at about $26,000. Atria Wealth Solutions Inc. bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at about $30,000. Cetera Investment Advisers bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at about $33,000. First Horizon Advisors Inc. bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at about $38,000. Finally, Endurance Wealth Management Inc. increased its position in Ginkgo Bioworks by 100.0% in the 1st quarter. Endurance Wealth Management Inc. now owns 10,000 shares of the company's stock valued at $40,000 after buying an additional 5,000 shares in the last quarter. 53.37% of the stock is owned by institutional investors and hedge funds.
Ginkgo Bioworks Stock Performance
NYSE:DNA opened at $2.99 on Wednesday. The stock has a market cap of $5.34 billion, a P/E ratio of -1.53 and a beta of 1.84. The stock has a 50 day simple moving average of $2.98 and a 200 day simple moving average of $3.10. The company has a current ratio of 11.84, a quick ratio of 11.78 and a debt-to-equity ratio of 0.03. Ginkgo Bioworks has a 1-year low of $2.09 and a 1-year high of $15.86.Ginkgo Bioworks Company Profile
(Get Rating)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
Featured Stories
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.